The MSH6 p.Leu585Pro mutation is associated with a nearly 50% lifetime risk of endometrial cancer and a 36% and 25% risk of CRC in males and females as well as a ∼12% lifetime risk of brain cancer (glioma). Here, MSH6 is linked to central nervous system cancer.